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1. Introduction
The COVID-19 pandemic is having severe conse-
quences for cancer patient care [1–5]. Cancer patient
screening and referrals are being delayed, ongoing clin-
ical trials are being brought to a halt, and new ones
are not being approved. Guidelines and clinical recom-
mendations for cancer patients have already been laid
out [1,3,5]. However, the cancer-related effect of the
pandemic is not restricted to patient care alone, but
has spread to cancer research funding – the two
aspects being inextricably linked.
National research budgets across Europe are threat-
ened by cuts following the economic damage caused by
the pandemic. European Union (EU) leaders and the
European Parliament agreed in early November to
adjust the budget of Horizon Europe — the research
and innovation framework of the EU for the period of
2021–2027 — down to 84.9 billion Euro, a significant
reduction compared to the original 94.4 billion Euro
proposal put forward by the commission in May [6–8].
The European Research Council (ERC), the funding
body that promotes excellence in research (including
high-risk high-reward cancer research), will also be lar-
gely affected by such cuts, with potential long-term con-
sequences for cancer research and cancer treatment [9].
But not all funding for cancer research comes from
governments and the EU [10]. In Europe, cancer chari-
ties provide funds for cancer research, in addition to
their roles in supporting patients more directly. So,
how have charities that support cancer research fund-
ing been affected? What challenges are they currently
being faced with, and what strategies will help them to
survive within a pandemic-disrupted cancer research –
cancer care ecosystem? We contacted European cancer
charities to collect data and perspectives on the pan-
demic-associated economic blow sustained so far, with
a special focus on consequences for cancer research
funding. Whilst several organizations are still gathering
data and planning their next steps, this article
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summarizes emerging evidence on the impact of the
COVID-19 pandemic on European cancer charities. In
addition, we highlight the need for innovative
approaches and reciprocal action to maintain a high
standard of cancer research.
2. Charities fuel cancer research
Cancer charities contribute to cancer care through
direct patient support [11], but their indirect contribu-
tion through cancer research funding is equally crucial.
European cancer charities provide financial aid for
cancer research and clinical trial testing, as well as
advocate for research with government and inform on
policy. The specific contributions of cancer charities to
research funding are diversified across Europe. Cancer
charities are the backbone of cancer research funding
in some Northern European countries, including the
Scandinavic countries and the UK. By contrast, in
Western Europe, financial support towards cancer
researchers by charities is seen as complementary to
national and European funding — although equally
crucial, as it creates space for demand-driven research
funding. Charitable cancer research funding remains to
be developed in Eastern Europe [12].
In all cases, however, cancer research funding by
cancer charities often enables breakthroughs in cancer
patient care by backing high-risk, high-reward research
not otherwise funded. Cancer charity investments are
also being used to indirectly foster collaborations
between scientists, for instance, through the establish-
ment of infrastructure for multidisciplinary research or
acquisition of cutting-edge technology. Scientific pro-
gress through cancer research might not be visible to
cancer patients until results materialize in the form of
a new treatment or new guidelines. Again, this is
where cancer charities can bridge such disconnect by
curating discussion forums, blog posts, and online
information pages, to highlight the significance of
advances in cancer research. These online platforms
also provide accurate cancer care guidance and tie in
information from various external resources, including
national health services.
3. The financial toll of the COVID-19
pandemic for European cancer
charities
A major route via which charities generate income is
fundraising. In response to the COVID-19 pandemic
in 2020, most European governments introduced self-
isolation and social distancing measures in early
March. Accordingly, European cancer charities had to
cancel or postpone fundraising events such as mara-
thons (e.g. Race for Life and Relay-for-Life), walks
(e.g. Kiltwalk and March for Men), flower sales, door-
to-door fundraising, coffee mornings and concerts.
This has translated in severe losses for charities that
heavily relied on the spring and summer fundraising
events (Table 1). Indicatively, the 2020 revenues from
races, festivals, dinner galas and concerts were reduced
by 10 million Euro for the Spanish Association
Against Cancer (AECC).
Safety measures also translated into reduced retail
activity of charity shops since they had to shut down,
further exacerbating their income shortfall. Most
charities rely on volunteers to keep events and retail
shops up and running. The pandemic safety measures
considerably reduced the number of available volun-
teers, the impact of which could echo into the coming
years.
Events that ultimately materialized earlier in the
year in a virtual format have had reduced success. For
instance, the Norwegian Cancer Society reported that
already in March they replaced their door-to-door
fundraising event ‘Krafttak mot kreft’ with a virtual
event, which was albeit met with limited success, end-
ing up to 1.7 million Euro short in profit. ‘Many peo-
ple are also facing their own financial uncertainty and
may be less able to give money to charity’ notes Dr
Rosie Loftus, Joint Chief Medical Officer at Macmil-
lan Cancer Support, a UK-based charity directly sup-
porting cancer patients. Echoing this remark, the
AECC disclosed a 2 million Euro shortfall in revenues
from private donors. Corporate support has equally
been affected: ‘most of our corporate partners have
deviated their corporate social responsibility budgets
to support COVID-19 emergency programs and initia-
tives. This has decreased our revenues from corporate
Table 1. Expected income loss per European cancer charity in











165 m 25% [11]
Cancer Society of Finland None None P.C.
Dutch Cancer Society 10–99 m N/A P.C.
French Cancer League 10 m 5–10% P.C.
Italian Foundation for
Cancer Research (AIRC)
20–25 m 20–25% P.C.
Spanish Association
Against Cancer (AECC)
20 m 23% P.C.
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support by 2–3 million Euro’, report AECC’s presi-
dent, Dr Ramon Reyes, and CEO, Noema Paniagua.
Back-up plans that some cancer charities relied on
for economic reinforcement of their budgets, such as
assets placed in financial investments, have in several
cases also fallen through. ‘Unfortunately, the financial
market is currently very volatile, and the value of
shares has plummeted. We expect a decrease in our
budgeted financial income by 2.8–4.6 million Euro if
the unrest in the financial markets does not subside’
explains N.M Compaore, Norwegian Cancer Society’s
Special Advisor of International Affairs.
4. Implications for cancer research
funding
In April, Cancer Research UK (CRUK), the UK’s
biggest contributor to cancer research funding, an
nounced an estimated reduction in future research gra
nts in the order of 20% [11]. This announcement came
with additional corollaries for grant applicants since
spring funding rounds were postponed to autumn,
increasing competition for available funding. This
unprecedented funding cut followed an expected com-
bined income loss of 25% of the CRUK annual bud-
get (~ £150 million, 165 million Euro), attributable to
the impact of COVID-19 on fundraising events and
retail activity [1,13]. In July, the projected annual
income loss was reported at 30% (~ 160 million GBPs,
177 million Euro), with a further loss of 300 million
GBPs expected in the next three years [14]. The latter
is bad timing especially for the UK, as by the end of
the Brexit transition period, rights to apply for EU
funding, including ERC grants, may be relinquished,
and hampered collaborations may further spark talent
loss [15,16]. Of note, the UK has so far ranked first
among ERC funding beneficiaries with over 1600
researchers securing ERC funding in 2007–2013, com-
pared to ~ 1000 beneficiaries in Germany or France
[17].
The COVID-19 financial toll has been felt by cancer
researchers all around Europe, as several European
cancer charities have announced delays in planned
calls for projects or are faced with income deficits
(Table 1). Initial estimations from the Dutch Cancer
Society report an income loss in the order of tens of
millions of Euros. Early estimates from the French
Cancer League indicate a setback in the order of 5–
10% of their income, a gap which may widen by the
end of the year. Equally, the Norwegian Cancer Soci-
ety has so far experienced losses of 12–13% of their
annual income. Moreover, the Italian Foundation for
Cancer Research (AIRC) and the AECC reported
income shortfalls of 20–25% in the 2020 budget. Char-
ities are also concerned about the long-term impact of
the pandemic on their income. Indicatively, the AECC
predicts a loss of 5 million Euro in their expected 2021
revenues, merely as a consequence of the earlier 3-
month collapse in new member donor acquisition.
The AECC notes that a budget of 17 million Euro
has been invested in cancer research this year, which is
smaller compared to previous years as a consequence
of delays or postponements of funding calls. Efforts to
circumvent this issue include the launch of new
research funding initiatives, such as the AECC Innova,
reopening of some calls for projects, and introduction
of programmes to sustain talent support and
strengthen clinical research. In addition to experienc-
ing delays in issuing funding to projects, French Can-
cer League’s cancer research budget could be cut by as
much as 20%. Whilst the AIRC can afford to dig ‘dee-
per’ into their reserve funding to avoid research-fund-
ing cuts in 2020–2021, their funding capacity may be
affected later on, as according to Professor Federico
Caligaris-Cappio, Scientific Director of AIRC, ‘. . .
from 2022 onward [it] will depend upon several differ-
ent and so far unpredictable variables and scenarios’.
5. Resilient charities: the other side of
the coin
However, not all European cancer charities have yet
had to issue funding cuts. For example, the Cancer
Society of Finland has not yet reported any income
loss, despite facing a fiercer competition for fundrais-
ing. Similarly, Fondation ARC in France have still not
felt the impact of the pandemic on their income. In
contrast to other European cancer charities, Fondation
ARC has maintained all planned calls for projects in
2020, confirmed no cuts to funding budgets and is
facilitating grant extensions for projects that have
secured funding. Furthermore, they launched a ‘Cancer
& COVID-19’ call for projects in April, with the scope
of expanding research into the interaction between can-
cer and other pathologies. They have also announced a
‘rescue’ budget to ensure the financial security of PhD
students and postdoctoral researchers who recently
started projects, but have suffered delays due to the
pandemic.
The Swedish Cancer Society appears equally
immune to the pandemic financial strain at the
moment. As key fundraising events were scheduled for
autumn, the Swedish Cancer Society was not severely
affected by early lockdown measures. This meant that
there was sufficient time to act swiftly with asset relo-
cation, as well as to adapt and include corporate
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partners in their financial strategies, which helped min-
imize financial shortfalls. It is worth noting that Swe-
den did not experience a strict lockdown in spring;
therefore, retail activity might have been less affected
in Sweden, compared to other European countries. As
such, the Swedish Cancer Charity announced a slight
stimulus in cancer research funding for this academic
year, with the prospect of a further increase the fol-
lowing year. ‘The Swedish Cancer Society realizes that
this is a critical time during which cancer research has
to be fostered, even if this would imply taking some
risks’ stated Ulrika Arehed Kagstr€om, Secretary Gen-
eral, Swedish Cancer Society.
Nevertheless, it is important to remember that the
pandemic is ongoing and lockdown rules of varying
severity could extend into the next 18–24 months in the
absence of a vaccine [18]. Equally, several European
cancer charities find that it is still early to accurately
assess the pandemic toll. This uncertainty perplexes the
broader European landscape that is currently perceived
as hostile for cancer researchers in need of financial sup-
port [7,8]. Thus, cancer research funding needs to be
safeguarded for the foreseeable future, and perhaps
European-wide initiatives need to be considered. Cancer
researchers and cancer patients depend on European
cancer charities and policymakers putting strategies in
place in anticipation of a long economic dry spell.
6. Innovation as a means to weather
the pandemic storm
‘Innovation and creativity have never been so crucial
[for charities]’, notes Dr Rosie Loftus, Joint Chief
Medical Officer at Macmillan Cancer Support.
Faced with cancellations and postponements of
fundraising events, cancer charities had to devise inter-
nal strategies to mitigate income loss, adapt to the new
norm of the pandemic lifestyle and as such modify
their fundraising efforts. Several cancer charities have
had to convert their fundraising efforts to fully virtual
or hybrid formats (Table 2).
A structural reorganization including recruitment of
personnel with digital competence helped to address
the new needs of the Swedish Cancer Society in the
current pandemic climate. ‘As digitalization requires
investment, and setting up new working modalities is
largely challenging, we need to regularly take a step
back and decide what the new core functions should
be, as well as monitor the situation closely’ notes
Ulrika Arehed Kagstr€om. Moreover, she indicated
that the phrasing of campaigns had to be adapted to
the new reality, as it is more crucial now than ever to
communicate notions with caution. ‘The message of
urgency must be delivered in a delicate manner, not
necessarily connecting to the pandemic’, she adds.
Along the same spirit, Macmillan Cancer Support
launched Games Night In, raising over 388, 000
GBPs/428, 000 Euro since April. The Dutch Cancer
Society is planning to broadcast a fundraising cam-
paign through national TV called ‘The Netherlands
will stand up to Cancer’ in an attempt to raise dona-
tions. Fondation ARC rescheduled most of its
fundraising activity to the end of the year as virtual
meetings, including ‘Journees Jeunes Chercheurs’
(‘Young Researcher days’) and the Griffuel Prize cere-
mony. As lockdown regulations were eased in France
in September, the Triathlon des Roses, a sports event
dedicated to women with breast cancer, materialized
following the latest safety guidelines.
Moreover, the French Cancer League is gearing up
active marketing campaigns to extend their fundraising
call throughout the year as well as planning to hold vir-
tual sports events. The Norwegian Cancer Society has
started organizing their annual ‘Pink Ribbon cam-
paign’, which aims to generate donations based on pin
sales and contributions of business partners in the name
of breast cancer. Likewise, the Swedish Cancer Society
involved corporate partners in their online retail activity
relating to their pink ribbon campaign. Nevertheless, in
the current COVID-19-inflicted financial crisis, it is
expected that cancer research charity partners may be
forced to restrict their contributions. However, there
could be other ways in which a mutually beneficial col-
laboration could be achieved between the two sectors.
‘We envision a flexible approach towards businesses
with which we have partnership agreements. . .’ says
N.M. Compaore, Norwegian Cancer Society.





Cancer Research UK Marathon race
Dutch Cancer Society TV broadcast show
Fondation ARC, France Triathlon
German Cancer Aid Marathon race
AIRC Flower sales
Macmillan Cancer Support Coffee morning
Games Night In
Game Heroes






Swedish Cancer Society Pink ribbon sales
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7. Fighting cancer together: building
alliances across sectors and borders
It is of paramount importance for cancer charities to
diversify their fundraising initiatives and develop inno-
vative strategies to secure a steady revenue. However,
extraordinary circumstances require extraordinary
measures, namely that cancer charities liaise with other
cancer charities as well as partners in industry and
governmental structures in pursuit of their mission in
this new landscape. The Nordic Cancer Union, a col-
laborative body promoting cooperation among the
Danish, Swedish, Finnish, Icelandic, Norwegian and
Faroese cancer societies, sets a good example of how
cancer charities could team up in times of crisis. In
addition, the Swedish Cancer Society has plans to
uphold cancer care by supporting patient organiza-
tions, which have been largely affected, mainly due to
their smaller size.
Ulrika Arehed Kagstr€om highlighted that collabora-
tions among European cancer charities could be part
of the solution: ‘We can work more closely together to
share examples of successful new paths. We also have
to remain outspoken about failures and losses, as even
a single stroke in cancer research funding in one of the
European countries will affect future cancer patients
globally’. Along the same lines, Ramon Reyes and
Noema Paniagua note: ‘we strongly believe it’s impor-
tant to share best practices and a common work
approach, as this isn’t an one runner challenge’. Flexi-
bility seems to be the new keyword in this rapidly
evolving pandemic situation, and flexible collabora-
tions could be the way forward for cancer charities,
which could focus on new ways to incentivize and
liaise with industry.
Foundations or third-party organizations from the
corporate sector could constitute key partners to can-
cer charities for mutual economic benefit and pan-
demic-related expenditure mitigation. Various regional
trusts, retail businesses, lotteries, banks and other
foundations in the UK have stepped up and offered
millions of pounds for charities affected by the virus
[19,20], and cancer charities would be eligible for some
of these funds.
Some governments are also offering support to can-
cer charities, especially in countries that rely more on
charity-sponsored cancer research. As part of a finan-
cial injection, the British government has devoted
750 million GBPs/825 million Euro to help charities
and hospices across the country following the after-
math of COVID-19 [21]. The British government also
matched public donations made at the national TV
broadcast event, BBC Big Night In, bringing the total
amount fundraised by this event to 77 million Euro
[21]. However, not all charities will be eligible for these
governmental funds, according to CRUK [22]. To fur-
ther support the supporters, the UK government has
relieved some costs from charities by deferring VAT
bills, exempting charity shops from business tax for a
year and covering a significant proportion of charity
staff salaries for those no longer working their regular
hours [21].
This economic injection, although generous, is hardly
adequate to account for immediate shortfall in funding
created by the pandemic, let alone the longer-term
effects. To put the figure of the financial rescue pack-
age announced by the UK government into perspec-
tive, the projected income loss due to COVID-19 was
estimated to be close to 13 billion Euro according to
the Chartered Institute of Fundraising and Charity
Finance Group [23]. Thus, CRUK has partnered
together with the UK Association of Medical Research
Charities to request 341 million Euro from the govern-
ment, specific to medical charities, as a fiscal ‘rescue’
package to narrow their revenue deficit in 2020/21 [24].
Cancer medical charities are also campaigning for Gift
Aid tax relief to be increased from 20% to 33% [25].
Whilst no governmental rescue packages aimed
specifically aimed cancer charities have been
announced across Europe, governments in Italy and
Norway are compensating cancer charities by finan-
cially supporting staff unable to work remotely. As in
the UK, the Norwegian government is now providing
reduced taxation for cancer charities. The French Can-
cer League and Cancer Society of Finland believe that
offering a reduced tax rate when taxpayers donate to
cancer charities could incentivize people to contribute
towards combating the impact of COVID-19 on char-
ity funding. Likewise, the 5 9 1000 scheme in Italy
has enabled AIRC to receive 60 million Euro in 2019,
in the form of donations equal to 0.5% of taxpayer
annual payments. Although contributions from this
scheme normally reach charities every two years, the
waiting time was reduced to one year given current
conditions.
Campaigning and government lobbying are becom-
ing increasingly decisive so that cancer charities can
attract monetary attention from European govern-
ments and foundations. The Norwegian Cancer Soci-
ety has been quite vocal in requesting support from
the Norwegian Ministry of Health and Care Services,
the Directorate of Health and various sustenance
schemes from foundations, with limited success. Like-
wise, the Dutch Cancer Society is in the process of
securing financial compensation for their budget from
the government.
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The European Commission can have a key role in
supporting an endagered and fragmented cancer
research funding landscape, especially in times of cri-
sis. Already in 2010, the European Commission
launched and co-financed a European network of can-
cer funding organisations, TRANSCAN. The TRANS-
CAN network involves ministries, funding agencies
and charities from about 20 countries across Europe.
Continuation of this project within Horizon Europe is
expected to ensure best use of the available (and occa-
sionally reduced) cancer research budgets of charities
and other organisations at the continental level, while
promoting international researcher collaborations.
While the pandemic threatens sustainability of cancer
research funding by charities, in the long run it may
accelerate international collaborations, as well as facili-
tate actions targeting policy makers and the general
public. The COVID-19 crisis has brought research and
health care in the limelight, forcing the public and politi-
cians to realize the core value, complexity and timeframe
of basic and translational research. This will boost the
potential of national and intersectional concerted cancer
plans and, hopefully, assist policies strategically formu-
lated to fight a longer-lasting epidemic such as cancer.
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